Industry Stakeholders Call for Balanced FDA Regulation on Household Hazardous Products - SPIK
Industry groups urged balanced FDA rules on hazardous products, supporting risk-based regulation and business competitiveness.
FDA Philippines, household hazardous products, HUHS regulation, Certificate of Product Registration, CPR requirements Philippines, ARTA consultation, risk-based regulation, Philippine Paint and Coatings Association, SPIK Philippines, regulatory reform Philippines
21723
wp-singular,post-template-default,single,single-post,postid-21723,single-format-standard,wp-theme-bridge,wp-child-theme-bridge-child,bridge-core-1.0.5,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,wpb-js-composer js-comp-ver-8.7.2,vc_responsive
Industry Stakeholders Call for Balanced FDA Regulation on Household Hazardous Products

01 Jun Industry Stakeholders Call for Balanced FDA Regulation on Household Hazardous Products

Posted at 11:20h in 2026 Events by
Spread the love

In a recent consultative meeting convened by the Anti-Red Tape Authority (ARTA), key representatives from the Philippine Paint and Coatings Association (PPCAI), Samahan sa Pilipinas ng mga Industriyang Kimika (SPIK), the Philippine Stationers Association (PSA), and the Board of Investments (BOI) came together to discuss pressing concerns over the Food and Drug Administration’s (FDA) Certificate of Product Registration (CPR) requirements for Household Urban Hazardous Substances (HUHS).

The meeting highlighted industry concerns about the current regulatory framework, particularly regarding the CPR requirements. Unlike global models, the Philippine regulation mandates oversight throughout the product lifecycle with inadequate risk-based justification or cost-benefit analysis. This approach has raised concerns regarding regulatory fairness and the practical impacts on market operations.

ARTA affirmed its commitment to reviewing the accumulated position papers and revisiting its 2020 recommendations advocating a risk-based regulatory approach. The Board of Investments also reaffirmed its support for streamlined, efficient regulations to foster investment and competitiveness in the sector. Together with the Department of Health (DOH) and FDA leadership, ARTA aims to facilitate further dialogues to develop a balanced regulatory framework that safeguards public health without unduly burdening industry.